A study of the recurrence score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen-receptor-positive breast cancer.

作者:Masuda N; Toi M; Ueno T; Yamanaka T; Saji S; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Saji S; Sasano H
DOI:10.1200/jco.2011.29.15_suppl.558
  • 出版日期2011-5-20